array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(112) "Empire Life Investments Inc. Makes New $5.03 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Empire Life Investments Inc. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 4,785 shares of the biopharmaceutical company's stock, valued at approximately $5,03" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-11-03/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1250fdd7-ae26-483d-bfbb-211135737c7f" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-11-03" ["categories"]=> array(5) { [0]=> string(12) "Stock Market" [1]=> string(11) "Regulations" [2]=> string(18) "General Investment" [3]=> string(19) "Investment Requests" [4]=> string(31) "Financial Update/Profit Warning" } } [1]=> array(7) { ["title_en"]=> string(58) "Piper Sandler Affirms Positive Outlook for Regeneron Stock" ["snippet_en"]=> string(167) "Piper Sandler maintains a positive outlook on Regeneron, upholding an Overweight rating with a target price of $1,242 amid competitive challenges and growth potential." ["url"]=> string(96) "https://investorshangout.com/piper-sandler-affirms-positive-outlook-for-regeneron-stock-103904-/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/cd508200-9961-4645-b4fd-863f273f762f" ["source"]=> string(20) "investorshangout.com" ["publication_date"]=> string(10) "2024-10-30" ["categories"]=> array(3) { [0]=> string(12) "Stock Market" [1]=> string(18) "General Investment" [2]=> string(24) "Stock Research & Ratings" } } [2]=> array(7) { ["title_en"]=> string(114) "Evercore sees Regeneron share price decline as overreaction, bullish on Dupixent as growth engine By Investing.com" ["snippet_en"]=> string(288) "Evercore ISI revised its outlook on Regeneron Pharmaceuticals (NASDAQ: REGN ) on Thursday, lowering its target price on the stock to $1,175.00 from $1,250.00, but maintaining an "Outperform" rating. This adjustment is in response to the expectation that rival drugs may be launched early." ["url"]=> string(63) "https://cn.investing.com/news/company-news/article-93CH-2528069" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-10-26" ["categories"]=> array(4) { [0]=> string(15) "Market Movement" [1]=> string(12) "Stock Market" [2]=> string(18) "General Investment" [3]=> string(14) "Product Launch" } } [3]=> array(7) { ["title_en"]=> string(65) "Regeneron shares: Morgan Stanley reiterates buy recommendation ()" ["snippet_en"]=> string(82) "Regeneron shares: Morgan Stanley reiterates buy recommendation () | aktiencheck.de" ["url"]=> string(106) "https://www.aktiencheck.de/news/Artikel-Regeneron_Aktie_Morgan_Stanley_bekraeftigt_Kaufempfehlung-17657988" ["image_url"]=> NULL ["source"]=> string(14) "aktiencheck.de" ["publication_date"]=> string(10) "2024-10-14" ["categories"]=> array(4) { [0]=> string(12) "Stock Market" [1]=> string(18) "General Investment" [2]=> string(14) "Issuing Shares" [3]=> string(16) "Share Repurchase" } } [4]=> array(7) { ["title_en"]=> string(50) "Regeneron to invest $1.8bn at Tarrytown, NY campus" ["snippet_en"]=> string(124) "Regeneron will invest $1.8 billion over six years to expand its manufacturing, support, and research facilities in New York." ["url"]=> string(99) "https://www.bioprocessintl.com/facilities-capacity/regeneron-to-invest-1-8bn-at-tarrytown-ny-campus" ["image_url"]=> string(78) "https://images.businessradar.com/articles/2ad9e98c-88e1-4f54-9f40-08786f5bce54" ["source"]=> string(18) "bioprocessintl.com" ["publication_date"]=> string(10) "2024-10-12" ["categories"]=> array(3) { [0]=> string(18) "Expansion & Growth" [1]=> string(20) "Business Development" [2]=> string(18) "General Investment" } } [5]=> array(7) { ["title_en"]=> string(124) "B & T Capital Management DBA Alpha Capital Management Invests $1.30 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(295) "B & T Capital Management DBA Alpha Capital Management purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-10-10/" ["image_url"]=> NULL ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-10-10" ["categories"]=> array(4) { [0]=> string(12) "Stock Market" [1]=> string(18) "General Investment" [2]=> string(19) "Investment Requests" [3]=> string(31) "Financial Update/Profit Warning" } } [6]=> array(7) { ["title_en"]=> string(100) "Anchor Investment Management LLC Sells 1,185 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Anchor Investment Management LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 81.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 275 shares of the biopharmaceutical company'" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-10-05/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/18d0ef4b-994d-4eae-adad-343da090c6af" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-10-05" ["categories"]=> array(6) { [0]=> string(12) "Stock Market" [1]=> string(10) "Divestment" [2]=> string(24) "Stock Research & Ratings" [3]=> string(11) "Regulations" [4]=> string(18) "General Investment" [5]=> string(31) "Financial Update/Profit Warning" } } [7]=> array(7) { ["title_en"]=> string(97) "Regeneron Pharmaceuticals Stock: Court Defeat Impacts Outlook - Downgrade! (First Group Research)" ["snippet_en"]=> string(114) "Regeneron Pharmaceuticals Stock: Court Defeat Impacts Outlook - Downgrade! (Erste Group Research) | aktiencheck.de" ["url"]=> string(136) "https://www.aktiencheck.de/exklusiv/Artikel-Regeneron_Pharmaceuticals_Aktie_Gerichtsniederlage_belastet_Aussichten_Herabstufung-17606302" ["image_url"]=> NULL ["source"]=> string(14) "aktiencheck.de" ["publication_date"]=> string(10) "2024-10-02" ["categories"]=> array(7) { [0]=> string(12) "Stock Market" [1]=> string(5) "Legal" [2]=> string(17) "Business Disputes" [3]=> string(24) "Stock Research & Ratings" [4]=> string(18) "General Investment" [5]=> string(8) "Verdicts" [6]=> string(17) "Commodity Pricing" } } [8]=> array(7) { ["title_en"]=> string(96) "Regeneron stock reaffirms buy opinion due to Goldman Sachs pipeline opportunity By Investing.com" ["snippet_en"]=> string(79) "Regeneron stock reaffirms buy opinion due to Goldman Sachs pipeline opportunity" ["url"]=> string(63) "https://kr.investing.com/news/company-news/article-93CH-1209225" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-09-25" ["categories"]=> array(3) { [0]=> string(12) "Stock Market" [1]=> string(18) "General Investment" [2]=> string(24) "Stock Research & Ratings" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc